|
|
Phase III Randomized Study of J-Pouch Coloanal Anastomosis Versus Side-to-End Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision in Patients With Mid- or Distal Rectal Adenocarcinoma
Alternate Title J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma
Objectives Primary
Secondary
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Patient Characteristics: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
Expected Enrollment 100A minimum of 100 patients (50 per treatment arm) will be accrued for this study. Outcomes Primary Outcome(s)Functional outcome as measured by a validated questionnaire Quality life as measured by a validated questionnaire Outline This is a randomized, multicenter study. Patients are stratified according to participating center and gender. Patients are randomized to 1 of 2 treatment arms.
In both arms, patients receive a temporary ileostomy. The ileostomy is closed after 1 week provided recovery is uneventful and no radiological signs of anastomotic leakage are detected. If early closure is not possible, the ileostomy is closed after 6-8 weeks. Functional outcome, quality of life, and anorectal function are assessed before surgery and at 4 and 12 months after surgery. Trial Lead Organizations Academisch Medisch Centrum at University of Amsterdam
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NCI Home |
Text-Only Version |
Contact Us |
Policies |
Accessibility |
RSS |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |